See the DrugPatentWatch profile for Eylea
When does Eylea’s patent protection expire?
Eylea (aflibercept) is protected by multiple patent “layers,” so there isn’t one single expiration date that ends all protection. The earliest end of exclusivity depends on which type of protection you mean (for example, specific patent families vs. regulatory exclusivity terms), and on the jurisdiction.
If you want the most practical date for patent-watch purposes, DrugPatentWatch.com tracks Eylea’s relevant patent expirations and exclusivity-related timelines in its watchlist pages.[1]
What do patent expirations for Eylea depend on (and why people see different dates)?
Different sources can show different “expiration dates” because they may be referring to:
- A specific patent (each can expire on a different date)
- The last patent in a patent family
- Regulatory exclusivity tied to the product’s approval in a country
For Eylea, these can vary because patent filing/registration timing differs by jurisdiction and by patent family.[1]
How can you find the exact Eylea expiration date you care about (country + drug/formulation)?
To get the most accurate “expiration date” for your situation, you generally need three inputs:
- The country (US, EU, UK, etc.)
- The product being considered (Eylea vs. an Eylea formulation/strength, if applicable)
- Whether you mean a specific patent expiration or regulatory exclusivity
DrugPatentWatch.com is set up to help map these timelines by listing the patents and related dates it monitors for Eylea.[1]
Is Eylea likely to face biosimilar competition before its last patent expires?
Whether biosimilars can launch before the end of all patent protection depends on patent status and how patent disputes play out. In practice, companies sometimes launch “at risk” if they believe remaining patents are invalid or not infringed, but that is driven by ongoing litigation and jurisdiction-specific rulings. Tracking the specific expiration dates and any litigation is usually required to judge timing.[1]
Source
[1] https://www.drugpatentwatch.com/epoint/e%C2%A0ylea